The EMPEROR-Reduced and DAPA-HF trials showed that SGLT2 inhibitors benefit HFrEF by reducing HHF, cardiovascular death and slowing renal function decline in chronic kidney disease (CKD) patients [85,86]. The gene discussed is SLC5A2; the disease is hydrops fetalis.